Skip to main content

Advertisement

SpringerLink
Log in

The road to resistance: EGFR mutation and cetuximab

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221–223).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Cetuximab sensitivity and resistance.

References

  1. Montagut, C. et al. Nat. Med. 18, 221–223 (2012).

    Article  CAS  Google Scholar 

  2. Jonker, D.J. et al. N. Engl. J. Med. 357, 2040–2048 (2007).

    Article  CAS  Google Scholar 

  3. Vermorken, J.B. et al. N. Engl. J. Med. 359, 1116–1127 (2008).

    Article  CAS  Google Scholar 

  4. Karapetis, C.S. et al. N. Engl. J. Med. 359, 1757–1765 (2008).

    Article  CAS  Google Scholar 

  5. De Roock, W. et al. Lancet Oncol. 11, 753–762 (2010).

    Article  CAS  Google Scholar 

  6. Amado, R.G. et al. J. Clin. Oncol. 26, 1626–1634 (2008).

    Article  CAS  Google Scholar 

  7. Bardelli, A. & Siena, S. J. Clin. Oncol. 28, 1254–1261 (2010).

    Article  CAS  Google Scholar 

  8. Wadlow, R.C. et al. Oncologist published online, 10.1634/theoncologist.2011-0452 (30 December 2011).

  9. Jänne, P.A., Gray, N. & Settleman, J. Nat. Rev. Drug Discov. 8, 709–723 (2009).

    Article  Google Scholar 

  10. Yonesaka, K. et al. Sci. Transl. Med. 3, 99ra86 (2011).

    Article  Google Scholar 

  11. Bertotti, A. et al. Cancer Discov. 1, 509–523 (2011).

    Article  Google Scholar 

  12. Benavente, S. et al. Clin. Cancer Res. 15, 1585–1592 (2009).

    Article  CAS  Google Scholar 

  13. Li, C., Iida, M., Dunn, E.F., Ghia, A.J. & Wheeler, D.L. Oncogene 28, 3801–3813 (2009).

    Article  CAS  Google Scholar 

  14. Lu, Y. et al. Cancer Res. 67, 8240–8247 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alberto Bardelli is at the Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Turin Medical School, Turin, Italy.,

    Alberto Bardelli

  2. Pasi A. Jänne is at the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.,

    Pasi A Jänne

Authors
  1. Alberto Bardelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pasi A Jänne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pasi A Jänne.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bardelli, A., Jänne, P. The road to resistance: EGFR mutation and cetuximab. Nat Med 18, 199–200 (2012). https://doi.org/10.1038/nm.2646

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2646

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation